Santosh Gupta, PhD
About Santosh Gupta, PhD
Santosh Gupta, PhD, is a Senior Biomarker and Translational Scientist at Epic Sciences in San Diego, California, where he has worked since 2021. He specializes in utilizing a multiomics approach to understand therapy resistance in cancer treatment and has extensive experience in developing molecular diagnostic tools.
Work at Epic Sciences
Santosh Gupta, PhD, serves as a Senior Biomarker and Translational Scientist at Epic Sciences, a company known for its focus on clarity in cancer diagnostics. He has held this position since 2021, contributing to the development of innovative biomarker strategies in San Diego, California. His role involves leading the strategic design and analysis of clinical biomarkers to support both early and late-phase clinical trials and drug development initiatives.
Education and Expertise
Santosh Gupta earned a Doctor of Philosophy (PhD) in Cancer Biology and Medical Biotechnology from the University of Turku and VTT Medical Biotechnology in Finland from 2006 to 2011. He also completed a Post-Doctoral Fellowship at Stanford University, focusing on Translational Research of Cancer, Biomarkers, and Immunotherapy from 2011 to 2015. Additionally, he studied Oncology and Regenerative Medicine at Duke University, achieving the Duke Scholar in Oncology and Regenerative Medicine designation. His expertise includes utilizing a multiomics approach to explain therapy resistance in cancer treatment.
Background
Before joining Epic Sciences, Santosh Gupta held various research positions in prestigious institutions. He worked as a Senior Research Scientist at Duke University Medical Center from 2015 to 2020 and as a Postdoctoral Researcher at Stanford University Medical Center from 2011 to 2015. His earlier experience includes roles at the Indian Institute of Science and VTT in Finland, where he focused on human genetics and oncology research.
Achievements
Santosh Gupta has made significant contributions to cancer research, particularly in the area of liquid biopsy tests for solid cancers. He played a key role in demonstrating the clinical utility and validity of these tests. He has also contributed to research on circulating tumor cell chromosomal instability and the neuroendocrine phenotype in prostate cancer. His work includes the development and validation of circulating tumor cell enumeration as a prognostic biomarker and participation in studies related to metastatic castration-resistant prostate cancer.